Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2021-06-28
Target enrollment:
Participant gender:
Summary
A double-blinded, randomized, placebo-controlled study will be performed to evaluate the
efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease
for 26 weeks.